Search research articles
Contact Us
Filters
Showing results (71-80 of 434) with videos related to
Page
of 44
Sort By:
Plos One
|
November 13, 2012
NLK is a novel therapeutic target for PTEN deficient tumour cells
Ana M Mendes-Pereira, Christopher J Lord, Alan Ashworth
Nature Reviews. Drug Discovery
|
November 13, 2019
Synthetic lethality as an engine for cancer drug target discovery
Alan Huang, Levi A Garraway, Alan Ashworth, et al.
Cancer Research Communications
|
November 26, 2025
Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells
Xuxu Gou, Huadong Chen, Morgan E Diolaiti, et al.
Cell
|
April 5, 2011
Genetic interactions in cancer progression and treatment
Alan Ashworth, Christopher J Lord, Jorge S Reis-Filho
The Journal of Pathology
|
November 6, 2009
Genomic instability and the selection of treatments for cancer
Sarah A Martin, Madeleine Hewish, Christopher J Lord, et al.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences
|
March 11, 2026
Comparative sequence analysis of the mouse pseudoautosomal region from three inbred strains reveals it to be the most rapidly evolving 'chromosome'
Takaoki Kasahara, Kazuyuki Mekada, Kuniya Abe, et al.
Nature Reviews. Clinical Oncology
|
September 1, 2011
Challenges translating breast cancer gene signatures into the clinic
Britta Weigelt, Lajos Pusztai, Alan Ashworth, et al.
BMC Developmental Biology
|
September 21, 2007
Neuregulin3 alters cell fate in the epidermis and mammary gland
Heena Panchal, Olivia Wansbury, Suzanne Parry, et al.
International Journal of Molecular Sciences
|
September 25, 2019
Klotho: A Major Shareholder in Vascular Aging Enterprises
Kenneth Lim, Arvin Halim, Tzong-Shi Lu, et al.
Human Molecular Genetics
|
August 21, 2003
Phenotypic effects of heterozygosity for a BRCA2 mutation
Madhuri Warren, Christopher J Lord, Julio Masabanda, et al.
Page
of 44
Search research articles
Search
Showing results (71-80 of 434) with videos related to
Sort By:
Page
of 44
Plos One
|
November 13, 2012
NLK is a novel therapeutic target for PTEN deficient tumour cells
Ana M Mendes-Pereira, Christopher J Lord, Alan Ashworth
Nature Reviews. Drug Discovery
|
November 13, 2019
Synthetic lethality as an engine for cancer drug target discovery
Alan Huang, Levi A Garraway, Alan Ashworth, et al.
Cancer Research Communications
|
November 26, 2025
Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells
Xuxu Gou, Huadong Chen, Morgan E Diolaiti, et al.
Cell
|
April 5, 2011
Genetic interactions in cancer progression and treatment
Alan Ashworth, Christopher J Lord, Jorge S Reis-Filho
The Journal of Pathology
|
November 6, 2009
Genomic instability and the selection of treatments for cancer
Sarah A Martin, Madeleine Hewish, Christopher J Lord, et al.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences
|
March 11, 2026
Comparative sequence analysis of the mouse pseudoautosomal region from three inbred strains reveals it to be the most rapidly evolving 'chromosome'
Takaoki Kasahara, Kazuyuki Mekada, Kuniya Abe, et al.
Nature Reviews. Clinical Oncology
|
September 1, 2011
Challenges translating breast cancer gene signatures into the clinic
Britta Weigelt, Lajos Pusztai, Alan Ashworth, et al.
BMC Developmental Biology
|
September 21, 2007
Neuregulin3 alters cell fate in the epidermis and mammary gland
Heena Panchal, Olivia Wansbury, Suzanne Parry, et al.
International Journal of Molecular Sciences
|
September 25, 2019
Klotho: A Major Shareholder in Vascular Aging Enterprises
Kenneth Lim, Arvin Halim, Tzong-Shi Lu, et al.
Human Molecular Genetics
|
August 21, 2003
Phenotypic effects of heterozygosity for a BRCA2 mutation
Madhuri Warren, Christopher J Lord, Julio Masabanda, et al.
Page
of 44